FindTrial
Sign In

Trastuzumab Injection

DRUG4 trials

Sponsors

Spanish Breast Cancer Research Group, Genor Biopharma Co., Ltd., UNICANCER, Jiangsu HengRui Medicine Co., Ltd.

Conditions

Breast CancerEarly-stage or Locally Advanced HER2-positive Breast CancerHER2-positive Metastatic Breast CancerLeptomeningeal DiseaseLeptomeningeal MetastasisMetastatic Breast Cancer

Phase 1

Clinical Trial of Comparative Study of GB221 Pharmacokinetics
CompletedNCT04175171
Genor Biopharma Co., Ltd.Metastatic Breast Cancer
Start: 2011-11-07End: 2012-03-08Updated: 2019-12-18

Phase 2

Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease
RecruitingNCT05800275
UNICANCERHER2-positive Metastatic Breast Cancer, Leptomeningeal Disease, Leptomeningeal Metastasis
Start: 2023-12-18End: 2027-06-30Target: 30Updated: 2025-11-18

Phase 3

Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer
CompletedNCT01875367
Spanish Breast Cancer Research GroupBreast Cancer
Start: 2013-09-18End: 2018-04-30Updated: 2023-04-05
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
RecruitingNCT07196774
Jiangsu HengRui Medicine Co., Ltd.Early-stage or Locally Advanced HER2-positive Breast Cancer
Start: 2025-10-23End: 2028-12-01Target: 740Updated: 2026-01-30

Related Papers

Abstract PS5-09-07: Etic-lm : a multicenter, single-arm, phase 2 study evaluating the efficacy of oral tucatinib, oral capecitabine, and intrathecal trastuzumab in patients with her2-positive metastatic breast cancer with leptomeningeal metastases, a ucbg study
Clinical Cancer Research2026-02-17
[Leptomeningeal disease in breast cancer: State of the art and future directions].
2025-05-28
A preferência de profissionais de saúde e pacientes pela via de administração da terapia sistêmica no tratamento do câncer de mama HER2-positivo: uma revisão sistemática da literatura
Jornal de Assistência Farmacêutica e Farmacoeconomia2023-11-08
Abstract OT3-01-03: Phase III clinical trial to evaluate patient's preference for subcutaneous (SC) versus intravenous (IV) trastuzumab administration in patients with HER2 positive, advanced breast cancer (ABC) under IV trastuzumab treatment for at least 4 months and without disease progression. ChangHER-SC study (GEICAM/2012-07)
Cancer Research2016-02-151 citations